GlassScriptPhysician profile
Robert T Polk
NPI 1982287314
$7,223.62
in general payments reported to CMS, 2019-2025
27 companies · $873 in 2025
The $873 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.73 · 2022: $449 · 2023: $3,125 · 2024: $2,750 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,643 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,642.74 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $959.67 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $916.36 | 2022-2025 | Caplyta |
| Abbvie INC. | $908.22 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $627.30 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $573.83 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $392.70 | 2022-2025 | Auvelity |
| Alkermes, INC. | $389.59 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Ironshore Pharmaceuticals INC. | $264.18 | 2023-2024 | Jornay Pm |
| Corium, LLC | $236.55 | 2023-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $229.27 | 2022-2024 | Quviviq |
| Tris Pharma INC | $218.39 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $207.20 | 2022-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $198.97 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $195.81 | 2023-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $166.73 | 2022-2024 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.80 | 2022-2023 | Belsomra |
| Phathom Pharmaceuticals, INC. | $105.63 | 2024 | Voquezna |
| Lundbeck LLC | $105.08 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Almatica Pharma LLC | $104.97 | 2023-2024 | Loreev Xr |
| Neos Therapeutics, LP | $69.78 | 2023-2024 | Adzenys Xr-Odt |
| Indivior INC. | $60.06 | 2023-2024 | Perseris |
| Amgen INC. | $48.44 | 2022 | |
| Antares Pharma, INC. | $42.35 | 2022 | |
| Livanova USA, INC. | $26.53 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $22.34 | 2023 | Secuado, Xelstrym |
| Biogen, INC. | $21.98 | 2024 | |
| Noven Pharmaceuticals, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Polk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.